Fennec Pharmaceuticals Inc. (NASDAQ: FENC)

Fennec Pharmaceuticals Inc. is a commercial stage specialty pharmaceutical company dedicated to preventing cisplatin-induced ototoxicity in pediatric and adolescent and young adult patients. The company focuses exclusively on the development and commercialization of PEDMARK ® , an FDA and European Commission approved therapy designed to reduce the risk of hearing loss associated with cisplatin chemotherapy in patients with localized, non-metastatic solid tumors. Fennec operates with the goal of establishing PEDMARK ® as the standard of care for ototoxicity prevention in oncology treatment.

Fennec generates revenue primarily through the sale of PEDMARK ® in the United States and through licensing and distribution agreements for PEDMARQSI ® in Europe, Australia, New Zealand, Turkey, and the Gulf Cooperation Council countries. The company receives upfront payments, milestone payments, and tiered royalties on net sales from its partners. In the U. S., Fennec sells PEDMARK ® directly through its own field force and medical science liaisons, supporting patient access via its Fennec HEARS ® program.

The company operates through the following segments:

• United States Commercial: This segment is responsible for the direct sale and distribution of PEDMARK ® within the United States. Fennec utilizes an experienced field force including Regional Pediatric Oncology Specialists and medical science liaisons to educate healthcare providers and support patient access. The Fennec HEARS ® program provides financial assistance, care coordination, and product access support to eligible patients regardless of insurance type.

• Europe, Australia, and New Zealand: This segment involves the licensing of PEDMARQSI ® to Norgine Pharma UK Limited for commercialization in the licensed territories. Under the agreement, Fennec received approximately $43 million in upfront consideration and is eligible for up to $230 million in additional milestone payments and double-digit tiered royalties on net sales. Norgine holds all marketing authorizations and is responsible for all commercialization activities in Europe, Australia, and New Zealand.

• Turkey and Gulf Cooperation Council: This segment involves a distribution agreement with Inpharmus for the commercialization of PEDMARK ® in Turkey and GCC countries. Inpharmus is responsible for certain regulatory, commercialization, and distribution activities, while Fennec supplies the product and receives payments under specified terms. Commercialization in these markets depends on obtaining and maintaining regulatory approvals and reimbursement.

Fennec holds a first-mover advantage as the developer of the first and only FDA- and EMA-approved therapy for cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company faces limited direct competition due to the niche indication and its strong intellectual property portfolio, including multiple patents extending to 2039 and orphan drug exclusivity in the U. S. until 2029 and pediatric-use marketing exclusivity in the EU until 2033. However, indirect competition exists from compounded sodium thiosulfate and off-label use of alternative agents, though none have demonstrated equivalent clinical evidence or regulatory approval for this specific indication.

Fennec serves pediatric oncology patients one month of age and older with localized, non-metastatic solid tumors receiving cisplatin-based chemotherapy, as well as adolescent and young adult patients up to 39 years of age with similar tumor profiles. The company targets treatment centers including children’s hospitals, academic oncology networks, and community oncology practices. Key institutional customers include members of the Children’s Oncology Group, National Cancer Institute-designated centers, and National Comprehensive Cancer Network affiliates. Fennec also engages with advocacy groups, payers, and healthcare providers to drive awareness and access to PEDMARK ® .